Operating Segments

3 Months Ended

Mar. 31, 2016

Operating Segments [Abstract]

Operating Segments

Note 8. Operating Segments

The Company maintains two active operating segments: BioTherapeutics and Vaccines/BioDefense. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

	Three Months Ended March 31,
	2016			2015
Contract/Grant Revenue
Vaccines/BioDefense	$	2,630,986		$	802,314
BioTherapeutics		-			13,972
Total	$	2,630,986		$	816,286
Income/(Loss) from Operations
Vaccines/BioDefense	$	317,991		$	84,681
BioTherapeutics		(1,245,585	)		(764,876	)
Corporate		(978,111	)		(878,072	)
Total	$	(1,905,705	)	$	(1,558,267	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	10,019		$	9,786
BioTherapeutics		10,433			48,374
Corporate		2,155			1,766
Total	$	22,607		$	59,926
Interest Income/(Expense)
Corporate	$	(3,885	)	$	561
Share-Based Compensation
Vaccines/BioDefense	$	28,006		$	24,592
BioTherapeutics		34,832			29,256
Corporate		73,573			88,177
Total	$	136,411		$	142,025

	As of March 31, 2016		As of  December 31,  2015
Identifiable Assets
Vaccines/BioDefense	$	1,150,768	$	2,123,676
BioTherapeutics		70,274		76,183
Corporate		4,369,978		5,187,263
Total	$	5,591,020	$	7,387,122